120 related articles for article (PubMed ID: 22524110)
1. [Antimicrobial peptides: a potential arsenal against HIV infection].
Castañeda-Delgado JE; Cervantes-Villagrana AR; Rivas-Santiago B
Invest Clin; 2012 Mar; 53(1):71-83. PubMed ID: 22524110
[TBL] [Abstract][Full Text] [Related]
2. [HIV infection. Virus resistance: development and prevention].
Link R; Miller V; Fätkenheuer G; Manegold C; Harrer T
Med Monatsschr Pharm; 1999 Mar; 22(3):86-8. PubMed ID: 10223868
[No Abstract] [Full Text] [Related]
3. HIV chemotherapy.
Richman DD
Nature; 2001 Apr; 410(6831):995-1001. PubMed ID: 11309630
[TBL] [Abstract][Full Text] [Related]
4. [Pathogenesis of HIV infection as the key to eradication? New therapeutic approaches].
Manegold C
MMW Fortschr Med; 2000 Mar; 142 Suppl 1():34-9. PubMed ID: 10863308
[TBL] [Abstract][Full Text] [Related]
5. [German-Austrian guidelines for antiretroviral therapy of HIV infection. (July, 2002, update)].
Brockmeyer NH; ;
Dtsch Med Wochenschr; 2003 May; 128 Suppl 1():S7-18. PubMed ID: 12736863
[No Abstract] [Full Text] [Related]
6. Potential Uses of Venom Proteins in Treatment of HIV.
Uzair B; Bushra R; Khan BA; Zareen S; Fasim F
Protein Pept Lett; 2018; 25(7):619-625. PubMed ID: 29956606
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial peptides from marine invertebrates: challenges and perspectives in marine antimicrobial peptide discovery.
Sperstad SV; Haug T; Blencke HM; Styrvold OB; Li C; Stensvåg K
Biotechnol Adv; 2011; 29(5):519-30. PubMed ID: 21683779
[TBL] [Abstract][Full Text] [Related]
8. HIV resistance and the developing world.
Gupta RK; Pillay D
Int J Antimicrob Agents; 2007 May; 29(5):510-7. PubMed ID: 17346940
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy in the management of HIV infection.
Vella S; Franca Pirillo M
Methods Find Exp Clin Pharmacol; 1996; 18 Suppl C():23-6. PubMed ID: 9003571
[No Abstract] [Full Text] [Related]
10. Saquinavir in the management of HIV infection.
Moyle G
Br J Hosp Med; 1997 Jun 4-17; 57(11):560-4. PubMed ID: 9307673
[TBL] [Abstract][Full Text] [Related]
11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
12. [Campaign against a chameleon. Therapeutic strategies to control a survival artist].
MMW Fortschr Med; 2000 Mar; 142 Suppl 1():80-1. PubMed ID: 10863320
[No Abstract] [Full Text] [Related]
13. Minidefensins and other antimicrobial peptides: candidate anti-HIV microbicides.
Cole AM
Expert Opin Ther Targets; 2003 Jun; 7(3):329-41. PubMed ID: 12783570
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoresistance: an emerging clinical problem.
Carosi G
J Biol Regul Homeost Agents; 1998; 12(1-2 Suppl):9-14. PubMed ID: 9689572
[No Abstract] [Full Text] [Related]
15. Antimicrobial peptides in the interactions between insects and flagellate parasites.
Boulanger N; Bulet P; Lowenberger C
Trends Parasitol; 2006 Jun; 22(6):262-8. PubMed ID: 16635587
[TBL] [Abstract][Full Text] [Related]
16. Why HIV drug resistance matters: an overview.
Learned J
Posit Aware; 2005; 16(5):26-30. PubMed ID: 16220604
[No Abstract] [Full Text] [Related]
17. Chemotherapy of human immunodeficiency virus (HIV) infection based on chemotherapeutic intervention with early steps of the virus replicative cycle.
De Clercq E
Postepy Biochem; 1995; 41(5 Suppl):338-42. PubMed ID: 8797234
[No Abstract] [Full Text] [Related]
18. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
Narciso P; Lazzarin A
Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial peptides for leishmaniasis.
Cobb SL; Denny PW
Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
[TBL] [Abstract][Full Text] [Related]
20. HIV suppression and risk of drug resistance mutations.
Phillips AN; Loveday C; Johnson MA
AIDS; 1998 Oct; 12(14):1930. PubMed ID: 9792396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
